Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares saw strong trading volume on Wednesday . 647,346 shares changed hands during mid-day trading, a decline of 81% from the previous session’s volume of 3,457,649 shares.The stock last traded at $15.12 and had previously closed at $15.16.

A number of analysts recently commented on the stock. ValuEngine upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Leerink Swann lifted their price objective on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the company an “outperform” rating in a research note on Thursday, February 8th. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, January 15th. Finally, Cowen restated a “buy” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $19.06.

How to Become a New Pot Stock Millionaire

The company has a current ratio of 5.60, a quick ratio of 5.53 and a debt-to-equity ratio of 0.47. The firm has a market cap of $2,810.85, a P/E ratio of -8.29 and a beta of 1.60.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.11). Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%. The business had revenue of $14.73 million for the quarter, compared to analyst estimates of $14.50 million. analysts predict that Amicus Therapeutics, Inc. will post -1.26 earnings per share for the current fiscal year.

In other news, CEO John F. Crowley sold 65,581 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $13.51, for a total transaction of $885,999.31. Following the completion of the transaction, the chief executive officer now directly owns 393,076 shares of the company’s stock, valued at approximately $5,310,456.76. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.71, for a total transaction of $73,550.00. Following the transaction, the insider now directly owns 69,184 shares of the company’s stock, valued at $1,017,696.64. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 207,870 shares of company stock valued at $3,066,112. Company insiders own 3.40% of the company’s stock.

Large investors have recently bought and sold shares of the company. Sage Capital Advisors llc purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at approximately $154,000. Engineers Gate Manager LP purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at approximately $155,000. Neuberger Berman Group LLC purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at approximately $196,000. Great West Life Assurance Co. Can increased its holdings in Amicus Therapeutics by 40.2% in the 3rd quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock worth $212,000 after acquiring an additional 4,145 shares in the last quarter. Finally, Sterling Capital Management LLC purchased a new stake in Amicus Therapeutics in the 3rd quarter worth $218,000.

ILLEGAL ACTIVITY WARNING: “Amicus Therapeutics (FOLD) Sees Unusually-High Trading Volume” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/03/14/amicus-therapeutics-fold-sees-unusually-high-trading-volume.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.